Patrick Jnea Partners 14, L... Net Worth

The estimated Net Worth of Patrick Jnea Partners 14, L... is at least 239 千$ dollars as of 27 March 2018. Patrick L owns over 707,964 units of TRACON Pharmaceuticals Inc stock worth over 239,154$ and over the last 7 years Patrick sold TCON stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Patrick L TCON stock SEC Form 4 insiders trading

Patrick has made over 1 trades of the TRACON Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Patrick bought 707,964 units of TCON stock worth 1,911,503$ on 27 March 2018.

The largest trade Patrick's ever made was buying 707,964 units of TRACON Pharmaceuticals Inc stock on 27 March 2018 worth over 1,911,503$. On average, Patrick trades about 707,964 units every 0 days since 2018. As of 27 March 2018 Patrick still owns at least 3,466,003 units of TRACON Pharmaceuticals Inc stock.

You can see the complete history of Patrick L stock trades at the bottom of the page.

Insiders trading at TRACON Pharmaceuticals Inc

Over the last 10 years, insiders at TRACON Pharmaceuticals Inc have traded over 6,301,907$ worth of TRACON Pharmaceuticals Inc stock and bought 27,278,043 units worth 151,387,355$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, TRACON Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of 15,278$. The most recent stock trade was executed by Management Inc. Opaleye on 10 November 2023, trading 4,764,008 units of TCON stock currently worth 1,381,562$.

What does TRACON Pharmaceuticals Inc do?

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w

Complete history of Patrick L stock trades at TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc executives and stock owners

TRACON Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Charles Theuer,
  President, Chief Executive Officer, Director
• Dr. Charles P. Theuer M.D., Ph.D.,
  CEO, Pres & Director
• Mark Wiggins,
  Chief Business Officer
• Mark C. Wiggins M.B.A.,
  Chief Bus. Officer
• Scott Brown,
  Chief Accounting Officer
• Scott B. Brown CPA, M.S.,
  Chief Financial Officer
• Suzy Benedict,
  Executive Vice President - Regulatory Affairs
• Stephen Worland,
  Independent Director
• J. Rainer Twiford,
  Independent Director
• Martin Mattingly,
  Independent Director
• William LaRue,
  Independent Director
• Saundra Pelletier,
  Director
• Bonne Adams,
  Executive Vice President - Clinical Operations
• Dr. Brenda Marczi Pharm.D., Pharmd Mba,
  Sr. VP of Regulatory Affairs
• Ya Huang,
  Exec. Director of Statistical Programming
• Bonne Adams,
  Exec. VP of Clinical Operations
• Dr. James L. Freddo,
  Chief Medical Officer
• Shahe Garabedian,
  Sr. VP & Head of Quality Assurance
• Ravi Nea Partners 14, L.P.N...,
  
• Peter W.Nea Partners 14, L....,
  
• Scott Dnea Partners 14, L.P...,
  
• Patrick Jnea Partners 14, L...,
  
• David Mnea Partners 14, L.P...,
  
• Anthony A. Jr.Nea Partners ...,
  
• Forestnea Partners 14, L.P....,
  
• Peter Jnea Partners 14, L.P...,
  
• M Jamesnea Partners 14, L.P...,
  
• Capital, Llc Ikarian Health...,
  
• Patricia L Bitar,
  CFO
• Forest Baskett,
  10% owner
• Patrick J Kerins,
  10% owner
• H Casey Logan,
  Chief Business Officer
• Peter J Barris,
  10% owner
• M James Barrett,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Peter W. Sonsini,
  10% owner
• Enterprise Associates 14, L...,
  
• Tracon Investment Fund Ii, ...,
  
• Paul Edward Walker,
  Director
• Ronald L Shazer,
  Chief Medical Officer
• Krishna Kittu Kolluri,
  10% owner
• Ravi Viswanathan,
  10% owner
• Theodore T Wang,
  Director
• Cross Border Opportunities ...,
  
• Cross Border Opportunities ...,
  
• Harry R Weller,
  10% owner
• Enterprise Associates 14, L...,
  
• Ryan D Drant,
  10% owner
• Super V3 Investment Limited...,
  10% owner
• Management Inc. Opaleye,
  10% owner
• Capital, Llc Ikarian Health...,
  
• Lisa Johnson Pratt,
  Director
• Carol C. Lam,
  Director